DREAMM-2: SINGLE-AGENT BELANTAMAB MAFODOTIN (GSK2857916) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) AND HIGH-RISK (HR) CYTOGENETICS
Author(s): ,
Adam D. Cohen
Affiliations:
Abramson Cancer Center, University of Pennsylvania,Philadelphia, PA,United States
,
Suzanne Trudel
Affiliations:
Princess Margaret Cancer Centre,Toronto, ON,Canada
,
Sagar Lonial
Affiliations:
Emory University, Winship Cancer Institute,Atlanta, GA,United States
,
Edward Libby
Affiliations:
Division of Medical Oncology,University of Washington,Seattle, WA,United States
,
Hans C. Lee
Affiliations:
MD Anderson Cancer Center,Houston, TX,United States
,
Britta Besemer
Affiliations:
Universitaetsklinikum Tuebingen,Tuebingen,Germany
,
Thierry Facon
Affiliations:
CHRU de Lille, Hôpital Claude Huriez,Lille,France
,
Ajay K. Nooka
Affiliations:
Emory University, Winship Cancer Institute,Atlanta, GA,United States
,
Natalie Callander
Affiliations:
University of Wisconsin, Carbone Cancer Center,Madison, WI,United States
,
Ajai Chari
Affiliations:
Icahn School of Medicine at Mount Sinai,New York, NY,United States
,
Ira Gupta
Affiliations:
GlaxoSmithKline,Upper Providence, PA,United States
,
Sofia Paul
Affiliations:
GlaxoSmithKline,Upper Providence, PA,United States
,
Joanna Opalinska
Affiliations:
GlaxoSmithKline,Upper Providence, PA,United States
Paul Richardson
Affiliations:
Dana-Farber Cancer Institute,Boston, MA,United States
EHA Library. Trudel S. 06/12/20; 293527; EP1037
Dr. Suzanne Trudel
Dr. Suzanne Trudel
Contributions
Abstract

Abstract: EP1037

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Patients with RRMM and HR cytogenetics have a poor prognosis and need effective therapies. In DREAMM-2 (NCT03525678), investigational single-agent belantamab mafodotin (an immunoconjugate targeting B-cell maturation antigen) demonstrated clinically meaningful activity and a manageable safety profile in patients with heavily pretreated RRMM (Lancet Oncol. 2020). We present outcomes in patients with HR cytogenetics (9-month follow-up).

Aims
-

Methods
Patients with RRMM who had provided informed consent received single-agent belantamab mafodotin (2.5 or 3.4 mg/kg). For this post hoc analysis, HR cytogenetics included t(4;14), t(14;16), 17p13del, or 1q21+ (tested locally).

Results
The median number of cycles was 3 (2.5: range: 1–15) and 4 (3.4: range: 1–14). Overall response rate (ORR; ≥partial response [PR] per independent review committee) was 27% in the 2.5 mg/kg group (22% with ≥very good partial response [VGPR]) and 40% in the 3.4 mg/kg group (27% with ≥VGPR; Table). The median duration of response (DoR) was not reached in the 2.5 mg/kg group and was 6.2 months in the 3.4 mg/kg group. The most common adverse events (>30% in either group) were consistent with the overall population (Lancet Oncol. 2020): keratopathy (2.5: 59%; 3.4: 79%), thrombocytopenia (2.5: 44%; 3.4: 65%), nausea (2.5: 27%; 3.4: 33%), anemia (2.5: 24%; 3.4: 42%), and blurred vision (2.5: 20%; 3.4: 42%). 

Conclusion
Patients with HR cytogenetics maintain deep and durable clinical responses with single-agent belantamab mafodotin, comparable to that reported in the overall population. The safety profile remained consistent with previous reports.

 

Funding: GlaxoSmithKline (205678). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical trial, Immunoconjugate, Multiple myeloma

© 2020 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2020 ASCO Annual Meeting. All rights reserved

Abstract: EP1037

Type: e-Poster

Presentation during EHA25: All e-Poster presentations will be made available on the on-demand Virtual Congress platform as of Friday, June 12 at 08:30 CEST and will be accessible until October 15, 2020.

Background
Patients with RRMM and HR cytogenetics have a poor prognosis and need effective therapies. In DREAMM-2 (NCT03525678), investigational single-agent belantamab mafodotin (an immunoconjugate targeting B-cell maturation antigen) demonstrated clinically meaningful activity and a manageable safety profile in patients with heavily pretreated RRMM (Lancet Oncol. 2020). We present outcomes in patients with HR cytogenetics (9-month follow-up).

Aims
-

Methods
Patients with RRMM who had provided informed consent received single-agent belantamab mafodotin (2.5 or 3.4 mg/kg). For this post hoc analysis, HR cytogenetics included t(4;14), t(14;16), 17p13del, or 1q21+ (tested locally).

Results
The median number of cycles was 3 (2.5: range: 1–15) and 4 (3.4: range: 1–14). Overall response rate (ORR; ≥partial response [PR] per independent review committee) was 27% in the 2.5 mg/kg group (22% with ≥very good partial response [VGPR]) and 40% in the 3.4 mg/kg group (27% with ≥VGPR; Table). The median duration of response (DoR) was not reached in the 2.5 mg/kg group and was 6.2 months in the 3.4 mg/kg group. The most common adverse events (>30% in either group) were consistent with the overall population (Lancet Oncol. 2020): keratopathy (2.5: 59%; 3.4: 79%), thrombocytopenia (2.5: 44%; 3.4: 65%), nausea (2.5: 27%; 3.4: 33%), anemia (2.5: 24%; 3.4: 42%), and blurred vision (2.5: 20%; 3.4: 42%). 

Conclusion
Patients with HR cytogenetics maintain deep and durable clinical responses with single-agent belantamab mafodotin, comparable to that reported in the overall population. The safety profile remained consistent with previous reports.

 

Funding: GlaxoSmithKline (205678). Drug linker technology licensed from Seattle Genetics; monoclonal antibody produced using POTELLIGENT Technology licensed from BioWa.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): Clinical trial, Immunoconjugate, Multiple myeloma

© 2020 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2020 ASCO Annual Meeting. All rights reserved

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies